| ¿µ¹® | carcinoembryonic antigen | ÇÑ±Û | ¾Ï¹è¾ÆÇ׿ø |
|---|---|---|---|
| ¼³¸í | ¿ø·¡ žÆÀÇ ÀåÁ¶Á÷¿¡¼ Á¤»óÀûÀ¸·Î Á¸ÀçÇÏ´Â ¹°Áú·Î žƱâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ ÀÖ´Â °æ¿ì¿¡ ¼ºÀο¡¼µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù. |
||
| ¿µ¹® | antigen | ÇÑ±Û | Ç׿ø |
|---|---|---|---|
| ¼³¸í | ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀÎ ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | fetal monitoring | ÇÑ±Û | žư¨½Ã |
|---|---|---|---|
| ¼³¸í | ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀÇ Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» žư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü žư¨½Ã¿Í ºÐ¸¸Áß Å¾ư¨½Ã·Î Å©°Ô ³ª´«´Ù. 1. ºÐ¸¸Àü žư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀÇ Å¾ÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. 1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼ ¾ç¼ö¸¦ ¾ò¾î¼ ºÐ¼®ÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼 ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù. 2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼ ±×°÷ÀÇ Ç÷°üÀ» ã¾Æ Ç÷¾×À» äÃëÇÏ¿© °Ë»çÇÏ´Â ¹æ¹ý. 3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î žư¡ Àڱüӿ¡¼ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â žÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. žÆÀÇ ¿îµ¿°ú žÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ žÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù. 4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ žƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ žư¡ ¹ÝÀÀÀ» ÇØ¼ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù. 5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» ÇØ¼ ½É¹Ú¼ö°¡ º¯ÈÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀÌ´Ù. 2. ºÐ¸¸Áß Å¾ư¨½Ã ºÐ¸¸µµÁß¿¡ žÆÀÇ °Ç°»óŸ¦ °¨½ÃÇÏ´Â °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ žư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀÇ Å¾ư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù. 1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú žÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù. 2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ žÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼ Ç÷¾×À» äÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼ žÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁÖ·Î °Ë»ç¸¦ ÇàÇÏ´Â Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù. |
||
| ¿µ¹® | fetal assessment | ÇÑ±Û | žƻçÁ¤ |
|---|---|---|---|
| ¼³¸í | ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀÇ Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» žư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü žư¨½Ã¿Í ºÐ¸¸Áß Å¾ư¨½Ã·Î Å©°Ô ³ª´«´Ù. 1. ºÐ¸¸Àüžư¨½Ã: ºÐ¸¸Çϱâ ÀÌÀüÀÇ Å¾ÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ¨ç ¾ç¼öõÀÚ: ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼ ¾ç¼ö¸¦ ¾ò¾î¼ ºÐ¼®ÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼 ½Ç½ÃÇÒ ¼ö ÀÖ´Ù. ¨è ÅÈÁÙõÀÚ: ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼ ÅÈÁÙ ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼ ±× °÷ÀÇ Ç÷°üÀ» ã¾Æ Ç÷¾×À» äÃëÇÏ¿© °Ë»çÇÏ´Â ¹æ¹ý. ¾ÆÁÖ À§ÇèÇÒ °Í °°Áö¸¸ »ó´çÈ÷ ¾ÈÀüÇÑ °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ´Ù¸¥ °Ë»ç¿¡ ºñÇØ¼ °Ë»ç¿¡ ¸¹Àº ±â¼úÀÌ ÇÊ¿äÇÏÁö¸¸ ¾ÆÁÖ ¸¹Àº Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù. ¨é ºñ½ºÆ®·¹½º°Ë»ç(nonstress test) : žƵµ Àڱà ¼Ó¿¡¼ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î žư¡ Àڱà ¼Ó¿¡¼ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â žÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. žÆÀÇ ¿îµ¿°ú žÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ žÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù. |
||
| ¿µ¹® | fetal alcohol syndrome | ÇÑ±Û | žƾËÄÚ¿ÃÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼ ÅÂ¾î³ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ªÀº°Ë¿, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù. |
||
| HCG, hCG | Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
| LFA | left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct... |
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| CFA | Chicken fetal antigen |
|---|---|
| FA-1 | Fetal Antigen 1 |
| FA-2 | Fetal Antigen 2 |
| OFA | Onco-Fetal Antigen |
| T-antigen | Thomsen Friedenreich antigen |
| fetal | Of or pertaining to a foetus, pertaining to in utero development after the embryonic period. (18 Nov 1997) |
|---|---|
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| antigen p150,95 | A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| antigen presentation | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen presenting cell | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen-presenting cells | Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation. (12 Dec 1998) |
| antigen processing | Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|